PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18790048-8	2008	These data confirm PDE5 expression, activity, and targeted inhibition by sildenafil in cardiomyocytes, as well as the role of this PDE in cardiomyocyte hypertrophy modulation.	Sildenafil Citrate	73-83	aldehyde dehydrogenase 7 family member A1	Homo sapiens	19-22	
12614192-3	2003	Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil (Viagra, Pfizer) - the first approved selective PDE inhibitor for the treatment of ED.	Sildenafil Citrate	107-117	aldehyde dehydrogenase 7 family member A1	Homo sapiens	166-169	
12614192-3	2003	Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil (Viagra, Pfizer) - the first approved selective PDE inhibitor for the treatment of ED.	Sildenafil Citrate	119-125	aldehyde dehydrogenase 7 family member A1	Homo sapiens	166-169	
12614192-4	2003	Sildenafil is inhibitory of PDE5 at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods.	Sildenafil Citrate	0-10	aldehyde dehydrogenase 7 family member A1	Homo sapiens	28-31	
12614192-4	2003	Sildenafil is inhibitory of PDE5 at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods.	Sildenafil Citrate	0-10	aldehyde dehydrogenase 7 family member A1	Homo sapiens	81-85	
10753463-1	2000	Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects.	Sildenafil Citrate	93-103	aldehyde dehydrogenase 7 family member A1	Homo sapiens	26-29	
12414329-7	2002	Sildenafil exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods.	Sildenafil Citrate	0-10	aldehyde dehydrogenase 7 family member A1	Homo sapiens	47-50	
16100293-1	2005	Differences in the clinical pharmacology of the 3 currently available oral phosphodiesterase-5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, are largely determined by their clinical pharmacokinetics as well as their PDE inhibitory activity profile.	Sildenafil Citrate	114-124	aldehyde dehydrogenase 7 family member A1	Homo sapiens	96-99	
15772499-1	2005	We examined the effects of the 5-phosphodiesterase (5-PDE) inhibitor sildenafil on pulmonary arterial pressure and some oxygen transport and cardiopulmonary parameters in humans during exposure to hypobaric hypoxia at rest and after exercise.	Sildenafil Citrate	69-79	aldehyde dehydrogenase 7 family member A1	Homo sapiens	54-57	
15633907-5	2004	International Guidelines has faced the problem of resuming sexual activity after a cardiac event and of the eventual suitability to the use of sildenafil or other selective inhibitor of cGMP-specific phosphodiesterase type 5 (5-PDE) for the therapy of ED in these patients.	Sildenafil Citrate	143-153	aldehyde dehydrogenase 7 family member A1	Homo sapiens	228-231